List of Excipients in Branded Drug ZILBRYSQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
UCB Inc	ZILBRYSQ	zilucoplan	50474-990	SODIUM CHLORIDE	2035-06-12
UCB Inc	ZILBRYSQ	zilucoplan	50474-990	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	2035-06-12
UCB Inc	ZILBRYSQ	zilucoplan	50474-990	SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE	2035-06-12
UCB Inc	ZILBRYSQ	zilucoplan	50474-990	WATER	2035-06-12

Zilbrysq Excipient Strategy and Commercial Opportunities

Last updated: August 13, 2026

Zilbrysq (zilucoplan) is a once-daily, subcutaneous complement C5 inhibitor supplied as a preservative-free, single-dose prefilled syringe. Its formulation uses a conventional aqueous peptide-injection platform: arginine hydrochloride for stabilization and tonicity, polysorbate 80 for interfacial protection, sodium chloride for osmolality control, and phosphate/phosphoric acid for pH management. The strongest commercial opportunities are in lifecycle reformulation, device integration, cold-chain reduction, global presentations, and differentiated self-administration rather than in replacing a single excipient.

The commercial case depends on Zilbrysq’s ability to compete with eculizumab, ravulizumab, efgartigimod and rozanolixizumab in generalized myasthenia gravis (gMG), while preserving treatment convenience and minimizing injection burden. FDA approved Zilbrysq in 2023 for adults with anti-acetylcholine receptor antibody-positive gMG, subject to a boxed warning and Risk Evaluation and Mitigation Strategy related to serious meningococcal infections [1].

What excipients are used in the Zilbrysq formulation?

Zilbrysq is a sterile aqueous solution containing zilucoplan and a short list of inactive ingredients. The product is supplied in three dose strengths: 16.6 mg/0.416 mL, 23 mg/0.574 mL and 32.4 mg/0.81 mL [1].

Component	Function in formulation	Commercial relevance
L-arginine hydrochloride	Stabilizer, solubility aid and tonicity contributor	May reduce peptide aggregation and adsorption
Polysorbate 80	Surfactant and interfacial stabilizer	Limits agitation-related and container-interface degradation
Sodium chloride	Tonicity adjustment	Supports injection tolerability
Sodium phosphate dibasic heptahydrate	Buffer component	Controls formulation pH
Phosphoric acid	pH adjustment	Fine-tunes buffer system and product stability
Water for injection	Vehicle	Standard parenteral solvent

The labeled formulation has an acidic-to-near-neutral pH of approximately 6.0 [1]. It is preservative-free and intended for single use. That design avoids antimicrobial-preservative compatibility issues but increases the importance of container closure integrity, syringe extractables, cold-chain control and dose-volume management.

Why was arginine selected for zilucoplan?

Arginine is a common excipient in peptide and protein formulations because it can improve apparent solubility and reduce self-association. For a synthetic peptide such as zilucoplan, arginine hydrochloride can also help manage aggregation, adsorption and concentration-related instability.

Arginine-based stabilization creates several development advantages:

• It can support a clear, low-viscosity liquid formulation.
• It may reduce the need for higher surfactant levels.
• It provides a formulation route compatible with subcutaneous delivery.
• It can help maintain product quality across refrigerated storage and controlled room-temperature excursions.

The main development risk is that arginine is not a universal stabilizer. Its impact depends on peptide sequence, charge distribution, concentration, pH and container surface. Reformulation programs should therefore assess aggregation by size-exclusion chromatography, particulate formation, peptide-related impurities, oxidation, deamidation and adsorption to syringe components.

A commercial supplier seeking to displace arginine would need to demonstrate equal or better stability without increasing injection volume, viscosity, osmolality or local tolerability.

How does the Zilbrysq excipient system compare with competing complement inhibitors?

Zilbrysq uses a relatively compact liquid formulation. Its closest commercial comparators use different molecular formats and administration routes, which creates distinct excipient and device strategies.

Product	Active ingredient	Mechanism	Administration	Formulation and commercial implication
Zilbrysq	Zilucoplan	C5 inhibition	Daily subcutaneous injection	Small-volume, preservative-free prefilled syringe
Soliris	Eculizumab	C5 inhibition	Intravenous infusion	Infusion-center formulation; hospital handling burden
Ultomiris	Ravulizumab	Long-acting C5 inhibition	Intravenous or subcutaneous, depending on presentation	Higher value placed on extended dosing and device performance
Vyvgart Hytrulo	Efgartigimod alfa plus recombinant hyaluronidase	FcRn blockade	Subcutaneous injection	Enzyme-enabled delivery platform and differentiated administration
Rystiggo	Rozanolixizumab	FcRn blockade	Subcutaneous injection	Monoclonal antibody formulation with dose-volume and injection-site constraints

Zilbrysq’s differentiator is daily self-administration rather than prolonged infusion intervals. That creates a tradeoff. The formulation can remain low volume, but the patient must tolerate frequent injections and maintain adherence. Commercial reformulation should focus on reducing injection burden, simplifying storage and improving ease of use.

What formulation patents and manufacturing barriers affect Zilbrysq?

The principal protection for zilucoplan is likely to involve the active peptide, sequence or analog structure, therapeutic use, formulations, dosage regimens and manufacturing processes. Public commercial analysis should separate these categories because they create different launch barriers.

Active-ingredient and composition claims

Composition-of-matter claims covering zilucoplan or closely related peptide analogs generally create the strongest barrier. They can restrict direct substitution even when a competitor uses a different excipient system.

Formulation claims

Formulation claims may cover combinations of:

• Zilucoplan concentration ranges
• Arginine or other amino-acid stabilizers
• Surfactant levels
• pH ranges
• Osmolality
• Liquid stability
• Low-temperature storage
• Prefilled syringe presentations

A competitor could avoid some formulation claims by replacing arginine, using a different buffer or changing the surfactant. That strategy is commercially meaningful only if the alternative remains stable in the same syringe and supports the same injection volume.

Method-of-use claims

Method-of-use protection may cover treatment of gMG, dosing schedules, antibody-positive patient populations or complement-mediated disease states. Such claims can remain relevant after composition claims expire, particularly where a generic or follow-on product seeks a narrow label.

Manufacturing and analytical barriers

Zilucoplan is a synthetic peptide, but manufacturing remains technically demanding. Key barriers include:

• Solid-phase peptide synthesis and cleavage control
• Removal of truncated and deletion sequences
• Control of oxidation and other peptide-related impurities
• Reproducible purification at commercial scale
• Sterile filtration and aseptic filling
• Control of visible and subvisible particles
• Stability in prefilled syringe materials
• Validated potency and complement-binding assays

Synthetic origin may reduce some biologic-manufacturing complexity, but it does not eliminate process-IP or analytical comparability risk.

What is the FDA regulatory status of Zilbrysq?

FDA approved Zilbrysq on October 17, 2023, for adults with anti-AChR antibody-positive generalized myasthenia gravis [1]. The product is subject to a boxed warning for serious meningococcal infections. Patients must receive meningococcal vaccination before treatment unless the risks of delaying treatment outweigh the risks of infection. The product is distributed through a restricted program, ZILBRYSQ REMS [1].

The approval has direct commercial consequences:

1. The eligible population is narrower than all gMG patients because the labeled indication requires anti-AChR antibody positivity.
2. The REMS adds onboarding and prescribing friction.
3. Vaccination and infection-risk counseling influence specialist adoption.
4. A reformulated product must preserve the clinical and regulatory profile while avoiding any new administration or immunogenicity concern.

Zilbrysq is a peptide drug, not a conventional monoclonal antibody. The principal generic pathway is therefore expected to involve an abbreviated application or other product-specific FDA route rather than a conventional biosimilar strategy under the Public Health Service Act. A follow-on applicant would still face substantial analytical, formulation, device and clinical-risk questions.

When does Zilbrysq lose exclusivity?

No reliable commercial launch forecast should use a single expiration date without separating regulatory exclusivity from patent protection. Relevant dates include:

Exclusivity category	Commercial effect
New chemical entity exclusivity	Can block certain abbreviated applications for the statutory period from FDA approval
Listed patents	May delay approval or launch after a Paragraph IV challenge
Pediatric exclusivity	Can add six months if awarded
Formulation patents	May extend protection for specific presentations
Method-of-use patents	May constrain labeled indications or carve-out strategies
Manufacturing patents	May increase switching costs without necessarily blocking all alternative processes

The FDA Orange Book is the controlling source for listed patents, regulatory exclusivity and any associated expiration dates for NDA 216834. Patent-family analysis should also review USPTO records, international filings and litigation dockets because formulation and manufacturing rights may not be fully reflected in the Orange Book [2,3].

What Paragraph IV challenges and litigation affect Zilbrysq?

A Paragraph IV challenge would require an applicant to certify that a listed patent is invalid, unenforceable or not infringed. The likely challenge targets would be:

• The zilucoplan active-ingredient claims
• Liquid formulation claims
• Prefilled-syringe or container claims
• Dosing and method-of-use claims
• Process claims that are difficult to design around

A first-filer could seek 180-day generic exclusivity if it satisfies the statutory requirements. The commercial value of that position would depend on whether the challenged patents cover the active peptide itself or only a particular formulation.

Public litigation analysis should distinguish among:

• Patent infringement complaints under the Hatch-Waxman framework
• Declaratory-judgment actions
• Patent-term or Orange Book listing disputes
• REMS-related access disputes
• Product-liability or injection-device cases

No litigation outcome should be inferred from a patent listing alone. A listed patent can be narrowed, invalidated, settled or left unasserted.

What excipient reformulation opportunities exist for Zilbrysq?

The most credible opportunities are incremental rather than radical.

Room-temperature stability

A formulation that tolerates longer room-temperature excursions could reduce specialty-pharmacy waste and simplify patient handling. Zilbrysq labeling permits limited room-temperature storage under specified conditions [1]. Extending that window would require evidence against aggregation, oxidation, particulate growth and syringe-material interaction.

Reduced injection volume

The approved doses already use sub-milliliter volumes. Further concentration increases could reduce injection burden, but higher peptide concentration may increase viscosity, aggregation or local tolerability problems. A successful program would need a coordinated excipient and device strategy.

Alternative surfactants

Polysorbate 80 is widely used but can generate degradation products and peroxide-related stress under some conditions. Alternatives such as poloxamers or newer nonionic surfactants may improve oxidative stability, but they can introduce new extractables, particle and regulatory questions.

Arginine replacement

Histidine, proline, sucrose, trehalose or other stabilizers could be screened as alternatives. Replacement is commercially attractive if it improves stability, enables a higher concentration or creates design-around distance from formulation claims. The risk is loss of solubility or increased peptide adsorption.

Dual-chamber or lyophilized presentation

A lyophilized Zilbrysq presentation could improve long-term stability or reduce cold-chain dependence. It would also add reconstitution steps, manufacturing complexity and adherence risk. That option is more credible for institutional use or markets with weak refrigerated distribution than for a daily self-injection product.

Device-compatible formulation

The highest-value opportunity may be an integrated formulation-device package: an autoinjector, low-force syringe, smaller needle or dose-confirmation system. Excipient changes should be evaluated with silicone oil, tungsten residues, elastomers, adhesives and contact materials used in the delivery system.

How strong is the Zilbrysq commercial opportunity?

Zilbrysq competes in a high-value specialist market with substantial unmet needs but strong alternatives. Its commercial position is strongest where patients need complement inhibition, prefer home administration and can manage daily dosing.

Revenue exposure is concentrated in:

• Anti-AChR-positive generalized myasthenia gravis
• Neuromuscular specialists and specialty pharmacies
• U.S. reimbursement and REMS execution
• Patient persistence with daily subcutaneous administration
• Competition from long-acting complement inhibitors and FcRn therapies

The principal upside comes from expanding practical use beyond patients who are poorly served by infusion therapies. The principal downside is treatment switching toward less frequent dosing. A better excipient system alone will not offset a dosing-frequency disadvantage, but it can improve persistence, storage convenience and supply-chain economics.

Which companies could challenge Zilbrysq?

Competitive pressure is likely to come from several categories:

• AstraZeneca, through Soliris and Ultomiris
• Argenx, through Vyvgart and Vyvgart Hytrulo
• UCB, through Zilbrysq itself and its neuromuscular commercial infrastructure
• Immunovant and other FcRn developers in the broader gMG market
• Generic or follow-on peptide manufacturers after relevant exclusivity barriers expire
• Specialty pharmaceutical companies pursuing alternate complement inhibitors

Excipient suppliers and contract development and manufacturing organizations can also participate through reformulation, fill-finish, syringe assembly, analytical testing and cold-chain optimization.

Key Takeaways

• Zilbrysq uses a conventional preservative-free aqueous peptide formulation based on arginine hydrochloride, polysorbate 80, sodium chloride and phosphate buffering.
• The most valuable excipient opportunities are room-temperature stability, concentration increase, lower injection burden and device compatibility.
• Arginine replacement and polysorbate 80 substitution could create formulation differentiation, but both require extensive peptide-stability and container-closure testing.
• Zilucoplan’s synthetic peptide status changes the follow-on regulatory analysis; biosimilar assumptions should not be applied automatically.
• The Orange Book and patent-family records for NDA 216834 should be used to determine exact patent expiration, exclusivity and Paragraph IV exposure.
• Zilbrysq’s main commercial risk is daily administration against longer-acting complement and FcRn competitors.
• Manufacturing, impurity control, sterile filling and syringe compatibility remain meaningful barriers even for a synthetic peptide.

FAQs About Zilbrysq Excipients and Commercial Strategy

Does Zilbrysq contain a preservative?

No. Zilbrysq is supplied as a preservative-free, single-dose subcutaneous injection.

Can polysorbate 80 in Zilbrysq be replaced?

Potentially. Poloxamers and other nonionic surfactants could be evaluated, but replacement would require confirmation of peptide stability, particle control, syringe compatibility and regulatory acceptability.

Is Zilbrysq a biologic for biosimilar purposes?

Zilucoplan is a synthetic peptide drug. Its follow-on pathway should be assessed under product-specific FDA requirements rather than assumed to follow the monoclonal-antibody biosimilar pathway.

What is the biggest formulation opportunity for Zilbrysq?

Improving temperature stability while maintaining the current small injection volume is likely the most commercially valuable formulation objective.

Can a generic manufacturer avoid Zilbrysq patents by changing the excipients?

Changing excipients may avoid selected formulation claims, but it will not necessarily avoid active-ingredient, method-of-use, manufacturing or device-related patents.

References

1. U.S. Food and Drug Administration. (2023). ZILBRYSQ (zilucoplan) injection, prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. United States Patent and Trademark Office. (n.d.). Patent Center.
4. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products.
5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.